LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Latigo Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 3, 2026
$14.30+0.30 (+2.14%)
Close on Oct 19, 2026
- Market cap
- $13.37M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Ownership
Who owns Latigo Biotherapeutics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
2 buys · 0 sales
Net bought $5.04M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| James B. Tananbaum | 9,181,328 | 14.50% | 13D (active) | Aug 10, 2026 |
| RA Capital Healthcare Fund, L.P. | 5,295,690 | 8.40% | 13G (passive) | Aug 10, 2026 |
| Deep Track Capital, LP | 4,446,656 | 7.03% | 13G (passive) | Aug 7, 2026 |
| Len Blavatnik | 3,185,177 | 5.00% | 13G (passive) | Aug 11, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nima Farzan | President and CEO, Director | 114,453 | 0.17% | Aug 6, 2026 |
| Neha Krishnamohan | CFO and Chief Business Officer | – | – | Aug 6, 2026 |
| Neil Singla | Chief Medical Officer | – | – | Aug 6, 2026 |
| Todd N. Smith | Director | – | – | Aug 10, 2026 |
| Beth C. Seidenberg | Director, 10% owner | 4,916,374 | 7.42% | Aug 10, 2026 |
| James B. Tananbaum | Director, 10% owner | 3,117,664 | 4.70% | Aug 10, 2026 |
| Timothy P. Walbert | Director | – | – | Aug 6, 2026 |
| Sara Bonstein | Director | – | – | Aug 6, 2026 |
| Kevin Raidy | Director | – | – | Aug 6, 2026 |
| 5AM Opportunities II (GP), LLC | 10% owner | – | – | Aug 12, 2026 |
| 5AM Opportunities II, L.P. | 10% owner | – | – | Aug 12, 2026 |
| Sanofi | 10% owner | 672,788 | 1.01% | Aug 12, 2026 |
| Andrew J. Schwab | 10% owner | – | – | Aug 12, 2026 |
| Kush Parmar | 10% owner | – | – | Aug 12, 2026 |
| 5AM Partners VI, LLC | 10% owner | 7,325,962 | 11.05% | Aug 12, 2026 |
| 5AM Ventures VI, L.P. | 10% owner | – | – | Aug 12, 2026 |
| Westlake BioPartners GP II, LLC | 10% owner | 27,956 | 0.04% | Aug 11, 2026 |
| Westlake BioPartners Opportunity Fund I, L.P. | 10% owner | – | – | Aug 11, 2026 |
| Westlake BioPartners Opportunity GP I, LLC | 10% owner | – | – | Aug 11, 2026 |
| Westlake BioPartners Fund II, L.P. | 10% owner | – | – | Aug 11, 2026 |
| Westlake BioPartners Fund I, L.P. | 10% owner | – | – | Aug 11, 2026 |
| Westlake BioPartners GP I, LLC | 10% owner | 4,995,328 | 7.53% | Aug 11, 2026 |
| Capital Fund VI LP Foresite | 10% owner | 3,414,544 | 5.15% | Aug 10, 2026 |
| Foresite Capital Fund V, L.P. | 10% owner | – | – | Aug 10, 2026 |
| Capital Management VI LLC Foresite | 10% owner | – | – | Aug 10, 2026 |
| Foresite Capital Management V, LLC | 10% owner | – | – | Aug 10, 2026 |
| Foresite Capital Opportunity Management V, LLC | 10% owner | – | – | Aug 10, 2026 |
| Foresite Capital Opportunity Fund V, L.P. | 10% owner | – | – | Aug 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| 5AM Partners VI, LLC 10% owner | Aug 10, 2026 | Conversion | +4,975,543 | – | – | 4,975,543 |
| 5AM Partners VI, LLC 10% owner | Aug 10, 2026 | Conversion | +2,350,419 | – | – | 2,350,419 |
| Sanofi 10% owner | Aug 10, 2026 | Conversion | +177,978 | – | – | 672,788 |
| Sanofi 10% owner | Aug 10, 2026 | Conversion | +494,800 | – | – | 494,800 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +1,484,401 | – | – | 4,995,328 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +3,464,072 | – | – | 3,510,927 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +1,027,635 | – | – | 5,944,009 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +165,519 | – | – | 5,160,847 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +2,066,857 | – | – | 2,094,813 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +3,547,842 | – | – | 4,916,374 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +938,979 | – | – | 1,368,532 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +3,547,842 | – | – | 4,916,374 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +938,979 | – | – | 1,368,532 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +1,027,635 | – | – | 5,944,009 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +3,464,072 | – | – | 3,510,927 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +1,484,401 | – | – | 4,995,328 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +165,519 | – | – | 5,160,847 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +2,066,857 | – | – | 2,094,813 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +296,880 | – | – | 3,414,544 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +3,117,664 | – | – | 3,117,664 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +3,117,664 | – | – | 3,117,664 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +445,320 | – | – | 3,562,984 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +1,125,823 | – | – | 1,125,823 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +742,201 | – | – | 1,868,024 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Buy | +140,000 | $18.00 | $2.52M | 2,008,024 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +195,776 | – | – | 2,203,800 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +3,117,664 | – | – | 3,117,664 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +445,320 | – | – | 3,562,984 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +296,880 | – | – | 3,414,544 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +1,125,823 | – | – | 1,125,823 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +742,201 | – | – | 1,868,024 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Buy | +140,000 | $18.00 | $2.52M | 2,008,024 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +195,776 | – | – | 2,203,800 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +3,117,664 | – | – | 3,117,664 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.